Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction

Daniel J. Sassoon,1 Johnathan D. Tune,1 Kieren J. Mather,2 Jillian N. Noblet,1 Mackenzie A. Eagleson,1 Abass M. Conteh,1 Joshua T. Sturek,1 and Adam G. Goodwill1

Diabetes 2017;66:2230–2240 | https://doi.org/10.2337/db16-1206

This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardiac contractile function at rest and in response to adrenergic stimulation in obese swine after myocardial infarction. Obese Osabaw swine were subjected to gradually developing regional coronary occlusion using an ameroid occluder placed around the left anterior descending coronary artery. Animals received subcutaneous injections of saline or liraglutide (0.005–0.015 mg/kg/day) for 30 days after ameroid placement. Cardiac performance was assessed at rest and in response to sympathomimetic challenge (dobutamine 0.3–10 μg/kg/min) using a left ventricular pressure/volume catheter. Liraglutide increased diastolic relaxation (dP/dt; Tau1/2; Tau1/e) during dobutamine stimulation (P < 0.01) despite having no influence on the magnitude of myocardial infarction. The slope of the end-systolic pressure volume relationship (i.e., contractility) increased with dobutamine after liraglutide (P < 0.001) but not saline administration (P = 0.63). Liraglutide enhanced the slope of the relationship between cardiac power and pressure volume area (i.e., cardiac efficiency) with dobutamine (P = 0.017). Hearts from animals treated with liraglutide demonstrated decreased β1-adrenoreceptor expression. These data support that GLP-1 agonism augments cardiac efficiency via attenuation of maladaptive sympathetic signaling in the setting of obesity and myocardial infarction.

Use of glucagon like peptide 1 (GLP-1)–based therapies for the treatment of type 2 diabetes (T2DM) has increased significantly since their discovery in the 1980s (1). Although these agents demonstrate unequivocal efficacy in the control of blood glucose concentration, an emerging body of evidence indicates direct cardiovascular benefit, including improvements in cardiac contractile function (2), reductions in myocardial infarct size (3) in animal studies, and improved cardiovascular event rates in some but not all clinical trials (4–6). Thus, there is strong interest in these apparent cardioprotective effects of GLP-1–based therapies in clinical applications of obesity and T2DM (7,8).

Prior studies of the cardiovascular effects of GLP-1 have largely been performed in animal models lacking obesity/metabolic disease phenotypes, in contrast to the fact that most patient populations treated with agents from this therapeutic class are overweight or obese (9). Studies from our laboratory and others have demonstrated obesity-related impairment in cardiovascular effects of GLP-1 agonists, including attenuation of GLP-1–mediated increases in myocardial glucose uptake in obese swine (10) and humans with T2DM (10,11). Further evidence of different responses in obesity comes from our recent report that the GLP-1R agonist exendin-4 augmented end-diastolic volume (EDV) and systolic pressure generation during coronary reperfusion in lean swine while maintaining systolic pressure despite marked reduction in diastolic filling in obese swine (12).

The mechanisms responsible for these obesity-related differences are unknown. However, the capacity for GLP-1 to induce changes in cardiac inotropy (13) and lusitropy (12) implicate underlying differences in adrenergic responsiveness that are known to exist in obesity (14). Such metabolic state–dependent effects of GLP-1 combined with the inconsistent cardiovascular benefits of GLP-1–based therapeutics in clinical trials of patients with diabetes (4,5)
support the need for a better understanding of the cardiac effects of GLP-1 in the setting of obesity and metabolic dysregulation, especially in the setting of complex ischemic heart disease.

This study investigated the potential for liraglutide to influence cardiac function at rest and in response to β-adrenergic receptor (βADR) stimulation in an obese swine model of subacute, progressive coronary artery occlusion. We hypothesized that chronic (~3–4 weeks) liraglutide administration (a GLP-1 analog) would demonstrate cardioprotective capacity in ischemic hearts of obese animals through infarct mitigation and/or alterations in cardiac contractile function.

RESEARCH DESIGN AND METHODS

Surgical Preparation and Experimental Protocol
All experiments involving animals were approved by an Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publica

Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publica

Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publica

Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publica

RESULTS
Phenotypic Characteristics of Obese Swine
Body weight on the day of ameroid placement was not different in animals subsequently assigned to receive saline versus liraglutide (P = 0.31) (Table 1). On randomized treatment, the liraglutide-treated animals failed to gain weight, resulting in significantly lower weight at the time of physiologic studies relative to saline controls (P = 0.02) (Table 1).

Liraglutide therapy did not significantly alter total cardiac mass (P = 0.85) (Table 1), heart weight-to-body ratio (P = 0.09) (Table 1), or the overall magnitude of infarction (P = 0.81) (Fig. 1). Also, left ventricular free wall thickness, measured 2 cm distal to the ameroid location, was not different between treatment groups (saline, 2.3 ± 0.1 vs. liraglutide, 2.3 ± 0.1 cm; P = 0.97).

Effects of Liraglutide on Baseline Hemodynamic and Cardiac Parameters
All physiologic data were obtained during an anesthetized procedure at the end of the treatment protocol (Table 2) for cross-sectional comparisons of saline versus liraglutide

| Table 1—Phenotype characteristics of obese swine |
|-----------------------------------------------|
|                   | Saline       | Liraglutide | P value |
| Body mass (kg)    | At ameroid placement | 63 ± 11  | 52 ± 4  | 0.31 |
|                   | At terminal study      | 70 ± 6  | 54 ± 3  | 0.02 |
| ΔBody weight (kg) |                       | 9 ± 4   | 1 ± 2   | 0.09 |
| Heart weight (g)  |                       | 223.3 ± 17.5 | 218.4 ± 13.9 | 0.85 |
| Heart weight-to-body weight ratio |           | 3.3 ± 0.04 | 4.1 ± 0.02 | 0.09 |

Values are mean ± SE for saline (n = 5) and liraglutide (n = 7).
treatment in the setting of subacute unrelied infarction. Mean arterial pressure was similar under resting conditions \((P = 0.87)\), but heart rate was \(\sim 40\%\) higher in liraglutide-versus saline-treated animals (Table 2). Heart rate changes (described below) occurred independent of changes to peripheral vascular resistance, which is calculated as mean arterial pressure/CO (saline: 0.03 \(\pm\) 0.004 vs. liraglutide, 0.03 \(\pm\) 0.005 mmHg/mL; \(P = 0.82\)). Key indices of cardiac function, including ejection fraction, \(\tau\) \(1/2\), end-diastolic PV relationship (Table 2), end-systolic elastance (\(E_{es}\)) (Fig. 2D), and CO (Fig. 3B) were unaffected by liraglutide administration under resting conditions.

**Effects of Liraglutide Treatment on Responses to Adrenergic Stimulation**

Systemic arterial pressures were not significantly increased by dobutamine (0.3–10 \(\mu\)g/kg/min) and were unaffected by liraglutide treatment (Table 2). Dobutamine increased heart rate in both groups, with an enhanced effect in liraglutide-treated animals \((P = 0.001)\) (Table 2) and reduced CO \((\sim 35\%; P = 0.02)\) in liraglutide-treated animals at the highest levels of dobutamine (Fig. 3B). Liraglutide treatment was also associated with enhanced diastolic function, as indicated by increases in \(-dP/dt_{min}\) and \(\tau\) (Table 2), consistent with the enhanced CO of liraglutide-treated animals \((P = 0.04)\) (Fig. 3B). End-diastolic PV relationships were unaffected by liraglutide treatment (Table 2).

Representative PV loops shown in Fig. 2A and B illustrate dobutamine-mediated reductions in EDV (right side of the PV loop), and end-systolic volume (ESV; left side of the PV loop), which decreased to a similar magnitude in both groups (EDV, \(P = 0.19\); ESV, \(P = 0.47\)). Stroke volume decreased similarly in both groups \((P = 0.48)\), reaching significance at the 10 \(\mu\)g/kg/min dose (saline, \(P = 0.005\); liraglutide, \(P = 0.02\)). Overall, the volume axis intercept \((V_{0c}\); greatest left ventricular volume at which pressure is zero) was lower in liraglutide-treated swine \((P < 0.001)\) (Fig. 2C). Load-dependent measures of cardiac contraction were enhanced by dobutamine in both groups, with dose-dependent increases in \(dP/dt_{max}\) \((P = 0.001)\) as well as significant reductions of contraction time in the liraglutide groups (Table 2). Accordingly, the mean relaxation was different between groups across the range of the dobutamine challenge \((dP/dt_{min}, P < 0.001; \tau_{1/2}, P = 0.06; \tau_{1/\tau}, P = 0.005)\). The slope of end-systolic PV relationship, a load-independent measure of cardiac contractility (\(E_{es}\)), was not different on average between groups \((P = 0.38)\) (Fig. 2D); however, dobutamine infusion significantly increased contractility at the 10 \(\mu\)g/kg/min dose in liraglutide- but not saline-treated animals \((P < 0.001)\) (Fig. 2D).

**Effect of Liraglutide and Adrenergic Stimulation on Cardiac Function and Efficiency**

EDV was significantly decreased relative to baseline in both saline- and liraglutide-treated animals at the highest concentrations of dobutamine \((P < 0.001\) for each group) (Fig. 3A). Dobutamine-dependent reductions in EDV were also similar between treatment groups \((P = 0.11)\) (Fig. 3A). Dobutamine-driven changes in CO were dose-dependently decreased in liraglutide-treated animals, achieving significance at the highest dose \((P = 0.02)\) (Fig. 3B). In saline-treated animals, which demonstrated modestly lower baseline CO values, CO was not significantly changed by dobutamine administration (Fig. 3B) despite significant increases in heart rate (Table 2).

PVA is linearly related to left ventricular myocardial oxygen consumption (\(MV_{O2}\)) (16) and was not different between treatment groups under resting conditions \((P = 0.29)\) or across the range of dobutamine exposures \((P = 0.43)\) (Fig. 3C). However, PVA was decreased compared with resting baseline in liraglutide-treated animals at 3.0 \((P = 0.005)\) and 10 \(\mu\)g/kg/min \((P < 0.001)\) dobutamine doses; there were no significant changes in PVA from baseline within the saline-treated animals (Fig. 3C).

Cardiac power (product of stroke volume, mean aortic pressure, and heart rate) was significantly increased under resting conditions by liraglutide treatment \((P = 0.03)\) and was greater in those animals across the range of dobutamine administration \((P = 0.04)\) (Fig. 3D). Dobutamine administration resulted in significant reductions in cardiac power at the 3 \(\mu\)g/kg/min \((P = 0.03)\) and 10 \(\mu\)g/kg/min \((P = 0.01)\) doses in liraglutide-treated animals (Fig. 3D).
|                | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamine | Liraglutide | Dobutamin|
Saline-treated animals, which showed lower cardiac power overall, demonstrated no change in cardiac power in response to dobutamine administration at any dose.

Figure 4 presents the relationship between CO and EDV for the saline- and liraglutide-treated animals before and during dobutamine administration. Liraglutide increased the slope of the relationship between CO and EDV with dobutamine challenge \((P = 0.002)\), resulting in greater CO at higher values of EDV. When cardiac power is expressed relative to PVA, it produces an index of cardiac work efficiency – power per unit of oxygen consumed \((16,17)\). Therefore, to assess whether liraglutide altered cardiac work efficiency, we plotted cardiac power relative to PVA (Fig. 5A). This relationship demonstrates that liraglutide treatment increased power generation at higher MVo2 \((P = 0.001)\) for slope of relationship saline vs. liraglutide by multiple linear regression; that is, cardiac efficiency was greater in liraglutide-treated animals. Figure 5B demonstrates that cardiac efficiency (ratio of cardiac power to PVA) was enhanced by liraglutide and that dobutamine challenge resulted in significant enhancement of efficiency in liraglutide- but not in saline-treated animals.

**DISCUSSION**

GLP-1 receptor activation produces potentially cardioprotective phenomena in healthy animal models receiving recombinant GLP-1–based therapies \((1–3,10,13,18)\). Inconsistent data exist regarding the cardioprotective potential of these therapies in the setting of ischemic heart disease with underlying obesity and metabolism dysfunction \((4–6)\). Because GLP-1–based therapies are classically used for the purpose of glucose regulation in T2DM, a population with significant lifetime cardiovascular risk, understanding the cardiovascular effects of GLP-1–based treatments in the setting of obesity is crucial.

Here we examined the effects of GLP-1 receptor activation via liraglutide on cardiac function at rest and in response to sympathetic stimulation in an obese swine model of slowly developing myocardial ischemia. We hypothesized that chronic \((3–4 weeks)\) administration of the GLP-1 analog liraglutide would demonstrate cardioprotective capacity in ischemic hearts of obese animals through infarct mitigation and/or alterations in cardiac contractile function. This study identifies the capacity of liraglutide to improve cardiac performance of significantly infarcted hearts in an energetically favorable fashion and is the first to identify a relationship between myocardial β1ADR abundance and GLP-1–based therapies.

**Infarct Size**

This study examined GLP-1–based cardioprotection in the context of a slowly developing, unrelieved, regional myocardial
infarction using an ameroid constrictor around the LAD. Ameroid constrictors are a well-established tool in the study of coronary artery disease in swine models (19,20). Post-mortem analyses verified a 100% closure rate of the ameroid constrictors in all study animals; that is, each animal experienced total loss of flow to the LAD perfusion territory distal to the ameroid constrictor. The consistency of closure between animals and treatment groups is evident in the tetrazolium staining, which demonstrated a consistent

15% infarction of the left ventricle (Fig. 1). This point is critical because these data demonstrate that differences in cardiac function with liraglutide administration are not related to underlying differences in the magnitude of infarction.

Data regarding the capacity of GLP-1 therapeutics to mitigate myocardial infarction remain equivocal because similar studies in swine from Kristensen et al. (21) and Ekström et al. (22) failed to show infarct mitigation, whereas Timmers et al. (3) and others have demonstrated infarct reductions with GLP-1–based therapies. Similarly equivocal findings exist in rodent models as well, which show varied capacity for infarct mitigation (23,24). Some discrepancy in the findings of the animal studies from different laboratories could arise as a result of the same factors that would limit or prevent exposure of ischemic tissues to receive the therapeutic agent and have important implications for the cardioprotective efficacy of GLP-1 therapies to mitigate infarct (26–29).

**Hemodynamics**

Pressor effects of GLP-1 are particularly pronounced in rodent models, which routinely show significant increases in mean pressure as high as 20 mmHg (13), inconsistent with human studies that report elevations of 2–3 mmHg or reductions of <3 mmHg in response to GLP-1 receptor agonism (8,13,14). The hemodynamic profile of liraglutide-treated animals in this study is consistent with work by Lovshin et al. (30), who found that 3 weeks of liraglutide treatment failed to modulate blood pressure in patients with T2DM. The absence of a significant pressor response in this study (Table 2) is therefore consistent with the body of literature in human subjects that demonstrates variable or modest effects of GLP-1 drugs on blood pressure (13).

Central effects of GLP-1 therapies to modulate hemodynamics are well established in rodents but remain equivocal in large-animal models and humans (13). Previous work by our group identified no effect of hexamethonium treatment on changes to cardiac performance resulting from acute administration of GLP-1 (7-36) in the setting of...
myocardial ischemia (2). These data further support an absence of sympathomimetic modulation by GLP-1–based therapies with regard to pressor responses because systolic, diastolic, and mean pressures are all consistent between treatment groups across the range of dobutamine concentrations. Similarly, GLP-1–mediated chronotropy (positive or negative) is highly variable and differs by species (13). Tachycardia appears to be most pronounced in species that demonstrate the greatest pressor responses to GLP-1 therapies (13), whereas meta-analyses of human studies report only modest GLP-1–related tachycardia (1).

In response to the sympathomimetic challenge, GLP-1 therapy resulted in a significantly higher heart rate across the dose response range (P = 0.001) (Table 1), although the magnitude of change relative to baseline was consistent between groups (P = 0.44). These data support a potential to modulate heart rate, but whether this is the result of nodal activity remains to be determined. To assess the potential of liraglutide to produce peripheral dilation, peripheral vascular resistance was calculated and not different between groups (P = 0.82), removing the potential of peripheral dilation to bias the result.

**Cardiac Function**
Liraglutide significantly lowered V0,a, an index of end-diastolic relaxation, both at baseline and at lower dobutamine concentrations. This decrease runs counter to previously documented effects of GLP-1 (7-36) administration in the setting of acute myocardial ischemia (2), where preload-dependent increases in CO were accomplished in a GLP-1–dependent fashion, reflected by a constant Ees and increased V0. However, prior observations were made in lean swine, whereas the current observations included only obese swine. The current findings are consistent with recent observations that demonstrated GLP-1 analog–dependent increases in inotropy of obese hearts in the setting of ischemia-reperfusion (12). These changes in V0 could reflect low levels of positive inotropy before overt increases in Ees or could be the result of significant and differential cardiac remodeling between the two treatment groups (31). Regardless, the contrast of the current data against those obtained in lean animals support the paradigm that metabolic status significantly affects the cardiac effects of GLP-1 therapies.

Contractility, as determined by Ees, was not enhanced with dobutamine challenge in saline-treated animals when examined as an absolute change or as a change relative to
baseline. By contrast, liraglutide therapies preserved the ability of infarcted hearts to respond to adrenoreceptor activation in that there was a continuous increase in Ees across the range of dobutamine concentrations both absolute and relative to baseline. Examination of the relationship between EDV and CO (Frank-Starling curve) (Fig. 4) reveals that liraglutide treatment results in a shift of the relationship of EDV to CO such that CO increases as EDV increases in liraglutide-treated animals relative to their saline counterparts. Classically, this relationship has been used to establish whether a system is demonstrating an inotropic response. We therefore interpret this set of observations as further evidence for a modest positive inotropic effect of liraglutide in the setting of significant myocardial infarction.

**Cardiac Efficiency**

Pioneering work by Suga (32,33) demonstrated a linear relationship between PVA and MvO₂. Therefore, the data obtained with transient inferior vena cava occlusion in this study enabled us to use PVA as an index of MvO₂. This index of oxygen consumption was similar between groups at baseline (P = 0.29). Despite similar PVAs, cardiac power (work per unit time; estimated here as the triple product of stroke volume, mean aortic pressure, and heart rate) was significantly greater at baseline in liraglutide-treated animals (Fig. 3D) at rest (P = 0.03) and over the range of dobutamine administration (P = 0.04). The relationship between cardiac power (work) and PVA (MvO₂) is an index of cardiac efficiency (Fig. 5). Owing to enhanced power without attendant increases in MvO₂, liraglutide treatment resulted in a significant enhancement of cardiac efficiency under conditions of enhanced metabolic demand imposed by dobutamine.

Obesity and ischemia-related heart failure are associated with reduced cardiac function and with impaired work efficiency (34,35), making therapies that simultaneously improve function and efficiency an attractive prospect. Our observations suggest that liraglutide may provide this advantageous combination of effects. The mechanism(s) underlying the improved work efficiency is of some interest. It is well recognized that utilization of fatty acids as a fuel source in the heart is accompanied by some ATP consumption unrelated to contractility through effects including an unfavorable phosphate-to-oxygen ratio, mitochondrial uncoupling, and futile cycling of metabolic intermediates (36). By corollary, switching away from fatty acid utilization can allow improved efficiency. Previous studies of GLP-1 agonists in animal models and in humans have described shifts in myocardial fuel selection toward glucose (11,37), with the important caveat that obesity and T2DM appear to induce resistance to these fuel-selection effects of GLP-1 agonists including in the swine model used in the current studies (10). The effects we observed were specific to the circumstance of acutely increased work under β-adrenergic stimulation. However, the response to acute increases in myocardial work under β-adrenergic stimulation is to preferentially utilize fatty acids, including mobilizing fatty acid stores from adipose tissue (36). The effect we observed prevailed despite these effects. Effects of GLP-1 on handling of metabolic intermediates, such as pyruvate (38) or effects to modulate mitochondrial handling of fuels or mitochondrial ATP production could help explain the observed effects but such phenomena have not been directly evaluated to

---

**Figure 6**—Liraglutide decreases expression of βADR. Liraglutide-treated animals exhibited significantly decreased left ventricular βADR abundance relative to saline-treated animals. Images show representative left ventricular myocardial staining for βADR in saline-treated (top) and liraglutide-treated (bottom) animals. Values are mean ± SE for saline (n = 4) and liraglutide (n = 4). †P < 0.05 vs. treatment same condition.
date. Further study of GLP-1 effects on myocardial substrate selection and ATP generation, evaluating the effects of treatment type, duration, and metabolic status as modulators of these effects is needed.

β1ADR Expression
In light of the different β-adrenergic responsiveness induced by liraglutide treatment, we evaluated β1ADR expression in the myocardium (Fig. 6). Unexpectedly, and in contrast to the observed enhancements of adrenergic responsiveness relative to saline-treated animals, the normally perfused myocardium of liraglutide-treated animals exhibited ~50% lower levels of β1ADR. This raises the possibility that liraglutide is affecting function and efficiency via effects on adrenergic responsiveness. It is well recognized that β1ADR antagonism can improve function in chronic heart failure (39) and that via effects to reduce fatty acid oxidation, β1ADR activation can improve work efficiency as well (40). Specific evaluations of effects on β-adrenergic responsiveness, and the role of adrenergic signaling as a modulator of GLP-1 agonist effects on contractility and work efficiency will help clarify the effect of the observed changes in receptor density.

Although the increased cardiac function in liraglutide-treated swine despite lower expression of β1ADR may seem paradoxical, this phenotypic combination has been previously observed as conferring benefit in other clinically relevant scenarios (41–43). Reduction in β1ADR signaling, via β-blockade, is frequently used to improve cardiac function, including in the setting of heart failure (44). Reducing β1ADR signaling disrupts the positive feedback loop (maladaptive adrenergic signaling) that pushes the heart toward hypertrophy and eventually failure (45) while also enhancing efficiency via decreased myocardial fat oxidation (40). Other ways that GLP-1 agonism might be influencing cardiac mechanical work without additional demand for myocardial oxygen uptake include effects on calcium handling (as seen, for example, with digoxin or milrinone) or effects on the contractile machinery (46). Prior proteomic studies performed by our laboratory (12) found that exendin-4, another GLP-1 agonist, changed the expression of key calcium-handling proteins, components and regulators of sarcomeric proteins, and protein mediators of intermediary metabolism.

Some efforts to explore the signaling mechanism supporting effects of GLP-1 on myocardial function have been undertaken. Noyan-Ashraf et al. (47) recently demonstrated significant enhancement to cardiac function with liraglutide therapies in obese mice that could be abolished through the application of an AMPK inhibitor. We previously found enhanced P38–mitogen-activated protein kinase activity in response to direct application of GLP-1 (7–36) to porcine myocardial slices (10). These pathways represent targets of further investigations to better understand the cardioprotective and hemodynamic effects of GLP-1–related therapies. Among other considerations is the question whether effects are exerted via direct effects on the canonical receptor, effects on a noncanonical receptor, or secondary effects resulting from effects in peripheral tissue. Our finding that responsiveness to adrenergic stimulation is preserved with liraglutide and that efficiency is improved in the treatment arm provides new opportunity for potentially translational applications of GLP-1–based therapies.

Limitations
Molecular analysis after euthanasia was limited by the need for intact, uncompromised heart slices for accurate infarct measurement. Formalin fixation and staining with tetrabromo-1,3-diaminobenzene prevented subsequent use of these tissues for gel-based analysis or ELISA. Biopsy samples from formalin-fixed tissues were used for immunohistochemistry. To minimize bias inherent to histologic analysis, we used digital pathology techniques to quantify stain. Liraglutide treatment was associated with decreased weight gain across the study, introducing modest differences in obesity at the time of the study. Although our power to demonstrate small effects was limited by the relatively small numbers of animals in the study, these samples were sufficient to identify large important effects on key outcome variables.

Conclusions and Implications
This study is the first to identify the potential for GLP-1–based therapies to modulate myocardial β1ADR abundance and, by extension, the potential for liraglutide therapies to improve cardiac performance of significantly infarcted hearts in an energetically favorable fashion via attenuation of maladaptive β1ADR signaling, similar to β-blockade therapies used to combat chronic heart failure. These findings could explain recent observations by Marso et al. (6), who found that the rate of fatal cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke was lower in liraglutide-treated patients with T2DM than the placebo group. Taken together, these data support that liraglutide (and potentially other GLP-1 agonists) therapies can augment cardiac efficiency and function through alterations to β1ADR expression and sensitivity, independent of changes to infarct area.

Funding. Support was provided by National Heart, Lung, and Blood Institute grant HL-117620 (J.D.T. and K.J.M., primary investigators) and by National Center for Advancing Translational Sciences grant TL1-TR-000162 (A. Shekhaw, primary investigator).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. D.J.S., J.N.N., M.A.E., A.M.C., and A.G.G. performed studies and reviewed and edited the manuscript. D.J.S. and A.G.G. wrote the manuscript. J.D.T. and K.J.M. contributed to discussion and reviewed and edited the manuscript. J.T.S. assisted with data analysis. A.G.G. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References
1. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:e001986
2. Goodwill AG, Tune JD, Noblet JN, et al. Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res Cardiol 2014;109:426

3. Timmers L, Henriques JP, de Klein DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501–510

4. Mogensen UM, Andersson C, Fosbol EL, et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus—a retrospective nationwide study. Diabetes Obes Metab 2014;16:1001–1008

5. Pfeffer MA, Claggott B, Díaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247–2257

6. Marso SP, Daniels GH, Brown-Andersson K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311

7. Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014;56:369–381

8. Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J Am Board Fam Med 2006;21:562–568

9. Qiao Q, Grandy S, Hiller J, Koestv K. Clinical and patient-related variables associated with initiating GLP-1 receptor agonist therapy in type 2 diabetes patients in primary care in Germany. PLoS One 2016;11:e0152231

10. Moberly SP, Mather KJ, Berwick ZC, et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol 2013;108:365

11. Geij M, Søndergaard HM, Stecher C, et al. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:E165–E1169

12. Sassoon DJ, Goodwill AG, Noblet JN, et al. Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism. Basic Res Cardiol 2016;111:43

13. Goodwill AG, Mather KJ, Conteh AM, Sassoon DJ, Noblet JN, Tune JD. Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord 2014;15:209–217

14. Haddock RE, Hill CE. Sympathetic overdrive in obesity involves purinergic hyperactivity in the resistance vasculature. J Physiol 2011;589:3289–3307

15. Berwick ZC, Dick GM, O’Leary HA, et al. Contribution of electromechanical coupling between Kv and Cav1.2 channels to coronary dysfunction in obesity. Basic Res Cardiol 2013;108:370

16. Suga H, Hayashi T, Shirahata M. Ventricular systolic pressure-volume area as predictor of cardiac oxygen consumption. Am J Physiol 1979;236:H498

17. Suga H. Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am J Physiol 1979;236:H498–H505

18. Suga H. Ventricular energetics. Physiol Rev 2011;90:247–277

19. How DJ, Assum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006;55:466–473

20. Knaapen P, Germans T, Knutti J, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation 2007;115:918–927

21. Lopaschuk GD, USsher JR, Holmes OD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207–258

22. Hansen J, Brock B, Batker HE, Gjedde A, Rungh J, Geij M. Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited. Rev Endocr Metab Disord 2014;15:219–231

23. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975–983

24. Connelly KA, Advani A, Zhang Y, et al. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: role of stromal cell-derived factor-1α. J Diabetes 2016;8:63–75

25. van den Wijngaard JP, Schulten H, van Horsen P, et al. Porcine coronary collateral formation in the absence of a pressure gradient remote of the ischemic border zone. Am J Physiol Heart Circ Physiol 2011;300:H1930–H1937

26. Margules KB, Hernandez AF, Redfield MM, et al.; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–508

27. Lenborg J, Kelbæk H, Vejstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Inter 2012;5:288–295

28. Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013;33:2252–2260

29. Lenborg J, Vejstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491–1499

30. Lovshin JA, Barmie A, DeAlmeida A, Logan A, Zimman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015;38:132–139

31. Burkhoff D, Mirlsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 2005;289:H501–H512

32. Suga H. Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am J Physiol 1979;236:H498–H505

33. Suga H. Ventricular energetics. Physiol Rev 1990;70:247–277

34. How DJ, Assum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006;55:466–473

35. Knaapen P, Germans T, Knutti J, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation 2007;115:918–927

36. Lopaschuk GD, Ussher JR, Holmes OD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207–258

37. Hansen J, Brock B, Batker HE, Gjedde A, Rungh J, Geij M. Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited. Rev Endocr Metab Disord 2014;15:219–231

38. Hall JL, Stanley WC, Lopaschuk GD, et al. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol 1996;271:H2320–H2329

39. Bristow MR, Gilbert EM, Abraham WT, et al.; MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807–2816

40. Sharma V, Dhillon P, Wambolt R, et al. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol 2008;294:H1609–H1620

41. Eckhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473–483

42. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43:1773–1779

43. Grover GJ, Kostis JB, Weiss HR, Li JK, Kovacs T, Kedem J. Effect of beta-adrenoceptor stimulation or blockade on regional myocardial function and regional
O2 consumption during myocardial ischemia. Arch Int Pharmacodyn Ther 1988;291: 68–87
44. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558–569
45. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 1997;80:7L–14L
46. ter Keurs HE. The interaction of Ca2+ with sarcomeric proteins: role in function and dysfunction of the heart. Am J Physiol Heart Circ Physiol 2012; 302:H38–H50
47. Noyan-Ashraf MH, Shikatani EA, Schuiki I, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 2013;127:74–85